S. Moe

5 ta ish

Doctors Without Borders

1. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan

   S. Moe, M. L. Rekart, D. Hernandez +9

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyThe International Journal of Tuberculosis and Lung Disease20232 iqtibos

   ABIABI:AkademIndex/2026.other.281628

2. Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

   S. Moe, I. Azamat, Sholpan Allamuratova +14

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyIJTLD OPEN20241 iqtibos

   ABIABI:AkademIndex/2024.article.001030

3. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

   Animesh A. Sinha, Robert J. Klebe, Michael L. Rekart +22

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyClinical Infectious Diseases20251 iqtibos

   ABIABI:AkademIndex/2025.article.000230

4. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

   Ilaria Motta, Martina Cusinato, Andrew Ludman +15

   MaqolaOAOchiq kirishCardiac electrophysiology and arrhythmiasAntimicrobial Agents and Chemotherapy20240 iqtibos

   ABIABI:AkademIndex/2024.article.000869

5. Characteristics, Treatment Strategies, and Long-term Health Outcomes of People With Bedaquiline-resistant Tuberculosis in Karakalpakstan, Uzbekistan—A Retrospective Cohort Study

   Matthew J Saunders, Ekaterine Garsevanidze, Sholpan Allamuratova +14

   MaqolaOAOchiq kirish20260 iqtibos

   ABIABI:AkademIndex/2026.article.038930